patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_727943 | REC_0009501 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 30 | 13.2 | 60 | male | 0 | 10 | 5.7 | 2 | pembrolizumab 200 mg q3w | 21.1 | true | MSS | 2026-03-15T05:35:59.204151+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905760 | REC_0009502 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 11.8 | 55 | female | 0 | 17 | 7.7 | 4 | entrectinib 600 mg daily | 8.5 | false | MSI-H | 2026-03-15T05:35:59.204400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358533 | REC_0009503 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 12.7 | 79 | female | 2 | 21 | 4.3 | 6 | entrectinib 600 mg daily | 7.2 | false | MSI-H | 2026-03-15T05:35:59.204639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546293 | REC_0009504 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 13.8 | 40 | female | 0 | 25 | 5.8 | 5 | sotorasib 960 mg daily | 17.1 | true | MSI-H | 2026-03-15T05:35:59.204956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262334 | REC_0009505 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 8.4 | 50 | female | 0 | 71 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 27.7 | true | MSS | 2026-03-15T05:35:59.205203+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_870051 | REC_0009506 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 7.5 | 62 | female | 0 | 24 | 7.5 | 5 | entrectinib 600 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:59.205447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_815552 | REC_0009507 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 11.4 | 72 | female | 2 | 24 | 5.6 | 6 | alectinib 600 mg BID | 16.8 | false | MSS | 2026-03-15T05:35:59.205698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_384863 | REC_0009508 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 13 | 74 | female | 2 | 3 | 5.1 | 1 | alectinib 600 mg BID | 9.5 | false | MSS | 2026-03-15T05:35:59.205948+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662393 | REC_0009509 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 4 | 66 | female | 1 | 52 | 5.9 | 1 | pembrolizumab 200 mg q3w | 23 | false | MSS | 2026-03-15T05:35:59.206194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660190 | REC_0009510 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 8.3 | 69 | male | 0 | 19 | 9.4 | 7 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:59.206443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143979 | REC_0009511 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 12.4 | 65 | female | 1 | 23 | 5.1 | 2 | alectinib 600 mg BID | 25.4 | true | MSS | 2026-03-15T05:35:59.206690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_120633 | REC_0009512 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 4.2 | 56 | female | 0 | 28 | 4.7 | 4 | pembrolizumab 200 mg q3w | 13.2 | false | MSS | 2026-03-15T05:35:59.206931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715323 | REC_0009513 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 4.8 | 73 | female | 2 | 75 | 6 | 6 | pembrolizumab 200 mg q3w | 9.8 | true | MSS | 2026-03-15T05:35:59.207182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598886 | REC_0009514 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 6.3 | 77 | female | 2 | 6 | 6.3 | 5 | osimertinib 80 mg daily | 13.4 | false | MSS | 2026-03-15T05:35:59.207423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397552 | REC_0009515 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 7.1 | 77 | female | 1 | 11 | 6.9 | 2 | osimertinib 80 mg daily | 17.6 | false | MSS | 2026-03-15T05:35:59.207661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905605 | REC_0009516 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 5.8 | 76 | female | 1 | 59 | 4.1 | 7 | pembrolizumab 200 mg q3w | 9.6 | true | MSS | 2026-03-15T05:35:59.207891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473065 | REC_0009517 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6 | 57 | male | 0 | 63 | 7 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.5 | true | MSS | 2026-03-15T05:35:59.208308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918420 | REC_0009518 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 27 | 12.1 | 70 | female | 3 | 10 | 3.9 | 0 | alectinib 600 mg BID | 41.4 | true | MSI-H | 2026-03-15T05:35:59.208567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351588 | REC_0009519 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 11.5 | 77 | female | 2 | 17 | 7.3 | 2 | osimertinib 80 mg daily | 20 | false | MSS | 2026-03-15T05:35:59.208806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467742 | REC_0009520 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 6 | 66 | female | 1 | 23 | 3.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.8 | false | MSS | 2026-03-15T05:35:59.209040+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534221 | REC_0009521 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 8.2 | 71 | female | 2 | 9 | 5.8 | 1 | alectinib 600 mg BID | 12.7 | true | MSS | 2026-03-15T05:35:59.209276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566368 | REC_0009522 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 8.5 | 52 | female | 0 | 33 | 6.2 | 3 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:59.209514+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535987 | REC_0009523 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.1 | 75 | female | 2 | 70 | 5.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.7 | false | MSS | 2026-03-15T05:35:59.209748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649756 | REC_0009524 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 25 | 13.7 | 73 | male | 2 | 7 | 5.7 | 0 | osimertinib 80 mg daily | 71.3 | false | MSI-H | 2026-03-15T05:35:59.209988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643347 | REC_0009525 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.7 | 68 | female | 1 | 28 | 4.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.1 | true | MSS | 2026-03-15T05:35:59.210220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963205 | REC_0009526 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 7.4 | 73 | female | 3 | 19 | 5.8 | 2 | pembrolizumab 200 mg q3w | 23.8 | true | MSS | 2026-03-15T05:35:59.210452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544228 | REC_0009527 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 16.6 | 71 | female | 2 | 13 | 7.6 | 7 | entrectinib 600 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:59.210687+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250270 | REC_0009528 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 9.1 | 72 | female | 1 | 7 | 4.9 | 7 | osimertinib 80 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:59.210918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320240 | REC_0009529 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 9.8 | 77 | female | 1 | 15 | 4.7 | 1 | osimertinib 80 mg daily | 11.5 | false | MSS | 2026-03-15T05:35:59.211150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829761 | REC_0009530 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 13.8 | 68 | female | 0 | 14 | 4.7 | 5 | alectinib 600 mg BID | 4.4 | true | MSI-H | 2026-03-15T05:35:59.211500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904662 | REC_0009531 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 15.1 | 61 | male | 1 | 10 | 4.8 | 5 | sotorasib 960 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:35:59.211751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_178822 | REC_0009532 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 16.9 | 65 | male | 1 | 28 | 4.1 | 1 | alectinib 600 mg BID | 23.1 | false | MSI-H | 2026-03-15T05:35:59.211995+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703684 | REC_0009533 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.3 | 64 | female | 0 | 22 | 4.1 | 7 | sotorasib 960 mg daily | 9.1 | false | MSS | 2026-03-15T05:35:59.212336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713199 | REC_0009534 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 18 | 65 | male | 1 | 17 | 6 | 9 | alectinib 600 mg BID | 7.2 | false | MSS | 2026-03-15T05:35:59.212601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143289 | REC_0009535 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 13.7 | 68 | male | 1 | 19 | 5.8 | 8 | alectinib 600 mg BID | 12.5 | false | MSI-H | 2026-03-15T05:35:59.212845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719582 | REC_0009536 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 28 | 13.1 | 72 | female | 2 | 17 | 4 | 0 | alectinib 600 mg BID | 46.8 | false | MSS | 2026-03-15T05:35:59.213082+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_898788 | REC_0009537 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 23.8 | 61 | female | 1 | 18 | 6.6 | 5 | osimertinib 80 mg daily | 13 | true | MSS | 2026-03-15T05:35:59.213322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829826 | REC_0009538 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 4.6 | 77 | male | 1 | 4 | 6.6 | 5 | pembrolizumab 200 mg q3w | 15.9 | true | MSS | 2026-03-15T05:35:59.213559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429840 | REC_0009539 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 32 | 12.5 | 71 | female | 1 | 17 | 5.5 | 0 | pembrolizumab 200 mg q3w | 36.1 | true | MSI-H | 2026-03-15T05:35:59.213798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778980 | REC_0009540 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 3.5 | 65 | male | 0 | 64 | 6.1 | 2 | pembrolizumab 200 mg q3w | 27.8 | true | MSS | 2026-03-15T05:35:59.214037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_170393 | REC_0009541 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 13.8 | 85 | female | 3 | 13 | 4.9 | 5 | osimertinib 80 mg daily | 6.7 | false | MSI-H | 2026-03-15T05:35:59.214277+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826027 | REC_0009542 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 17.5 | 82 | female | 1 | 10 | 4 | 6 | osimertinib 80 mg daily | 8.4 | false | MSI-H | 2026-03-15T05:35:59.214520+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310703 | REC_0009543 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.6 | 51 | male | 0 | 52 | 7.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.5 | false | MSS | 2026-03-15T05:35:59.214886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553938 | REC_0009544 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 12.2 | 73 | female | 2 | 19 | 3.9 | 2 | osimertinib 80 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:59.215135+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824273 | REC_0009545 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 2.3 | 85 | female | 1 | 14 | 2.1 | 5 | alectinib 600 mg BID | 9 | false | MSS | 2026-03-15T05:35:59.215373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919128 | REC_0009546 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 5.7 | 58 | female | 0 | 13 | 5.5 | 5 | alectinib 600 mg BID | 14.6 | false | MSS | 2026-03-15T05:35:59.215611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500866 | REC_0009547 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 19.5 | 52 | male | 0 | 21 | 6.2 | 2 | alectinib 600 mg BID | 23.1 | false | MSS | 2026-03-15T05:35:59.215850+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896007 | REC_0009548 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.4 | 58 | female | 0 | 16 | 6.3 | 4 | pembrolizumab 200 mg q3w | 12.1 | false | MSS | 2026-03-15T05:35:59.216140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812840 | REC_0009549 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 5.5 | 61 | male | 0 | 23 | 7.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.4 | true | MSS | 2026-03-15T05:35:59.216396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764990 | REC_0009550 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 14.3 | 82 | male | 3 | 18 | 7.1 | 2 | osimertinib 80 mg daily | 16.2 | true | MSI-H | 2026-03-15T05:35:59.216639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748020 | REC_0009551 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6 | 81 | female | 1 | 68 | 4 | 6 | carboplatin + paclitaxel + pembrolizumab | 15 | true | MSS | 2026-03-15T05:35:59.216876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832023 | REC_0009552 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 17 | 4.9 | 61 | male | 0 | 77 | 4.5 | 8 | pembrolizumab 200 mg q3w | 8.4 | false | MSS | 2026-03-15T05:35:59.217112+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_854610 | REC_0009553 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 4.5 | 58 | female | 0 | 50 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.3 | false | MSS | 2026-03-15T05:35:59.217346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616297 | REC_0009554 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 6.3 | 74 | female | 1 | 40 | 6.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 12 | true | MSS | 2026-03-15T05:35:59.217577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238230 | REC_0009555 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 15.4 | 63 | male | 0 | 11 | 5.5 | 2 | osimertinib 80 mg daily | 14.8 | true | MSS | 2026-03-15T05:35:59.217814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485938 | REC_0009556 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 8.9 | 79 | male | 2 | 18 | 5.3 | 2 | entrectinib 600 mg daily | 24.8 | false | MSS | 2026-03-15T05:35:59.218154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624130 | REC_0009557 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.5 | 72 | female | 1 | 14 | 5.9 | 6 | sotorasib 960 mg daily | 16.6 | false | MSI-H | 2026-03-15T05:35:59.218393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467552 | REC_0009558 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 10.1 | 72 | female | 2 | 4 | 4.2 | 7 | sotorasib 960 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:59.218624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534423 | REC_0009559 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 13 | 17.6 | 75 | female | 3 | 19 | 6.5 | 6 | osimertinib 80 mg daily | 6.8 | true | MSS | 2026-03-15T05:35:59.218860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597801 | REC_0009560 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11.1 | 71 | female | 1 | 17 | 4.1 | 7 | osimertinib 80 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:35:59.219095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_531571 | REC_0009561 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 7.8 | 76 | female | 1 | 15 | 4.9 | 4 | pembrolizumab 200 mg q3w | 5.4 | false | MSS | 2026-03-15T05:35:59.219322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996539 | REC_0009562 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 9.9 | 64 | female | 1 | 13 | 6.2 | 6 | osimertinib 80 mg daily | 6.6 | true | MSS | 2026-03-15T05:35:59.219552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574341 | REC_0009563 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 17.4 | 65 | female | 1 | 11 | 5.8 | 2 | osimertinib 80 mg daily | 15.4 | true | MSS | 2026-03-15T05:35:59.219787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865547 | REC_0009564 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 9.4 | 71 | female | 0 | 19 | 5.9 | 8 | sotorasib 960 mg daily | 7.5 | true | MSS | 2026-03-15T05:35:59.220014+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_898308 | REC_0009565 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12.3 | 58 | female | 0 | 19 | 5.1 | 5 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:59.220285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777616 | REC_0009566 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 9.7 | 73 | female | 1 | 55 | 4.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 11.9 | false | MSS | 2026-03-15T05:35:59.220517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540873 | REC_0009567 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.8 | 65 | female | 1 | 72 | 5.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.5 | true | MSS | 2026-03-15T05:35:59.220757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944951 | REC_0009568 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11 | 79 | female | 2 | 8 | 7.3 | 5 | osimertinib 80 mg daily | 14.6 | true | MSS | 2026-03-15T05:35:59.220988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105505 | REC_0009569 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 11 | 60 | female | 0 | 28 | 6.1 | 2 | sotorasib 960 mg daily | 21 | true | MSS | 2026-03-15T05:35:59.221270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673515 | REC_0009570 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 15.4 | 63 | female | 1 | 13 | 5.9 | 4 | entrectinib 600 mg daily | 20.6 | false | MSS | 2026-03-15T05:35:59.221508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887943 | REC_0009571 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 10.4 | 71 | female | 2 | 14 | 7.6 | 1 | entrectinib 600 mg daily | 25.2 | false | MSI-H | 2026-03-15T05:35:59.221743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254606 | REC_0009572 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 13.4 | 66 | male | 1 | 19 | 6.5 | 5 | osimertinib 80 mg daily | 6.8 | true | MSI-H | 2026-03-15T05:35:59.221981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_580803 | REC_0009573 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 10.4 | 64 | female | 1 | 19 | 5 | 5 | sotorasib 960 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:59.222216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222641 | REC_0009574 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 10.7 | 71 | female | 2 | 4 | 5.5 | 6 | osimertinib 80 mg daily | 12.6 | false | MSI-H | 2026-03-15T05:35:59.222448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421138 | REC_0009575 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 12.2 | 75 | female | 2 | 8 | 6.6 | 8 | osimertinib 80 mg daily | 17.5 | false | MSS | 2026-03-15T05:35:59.222680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798674 | REC_0009576 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 29 | 19.3 | 60 | female | 0 | 3 | 6 | 1 | pembrolizumab 200 mg q3w | 17.8 | false | MSI-H | 2026-03-15T05:35:59.222913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329134 | REC_0009577 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 11.6 | 76 | female | 2 | 14 | 4 | 5 | entrectinib 600 mg daily | 10.9 | false | MSI-H | 2026-03-15T05:35:59.223146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119945 | REC_0009578 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 10.3 | 52 | female | 0 | 18 | 5 | 3 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:59.223378+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242372 | REC_0009579 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 10.8 | 62 | male | 0 | 21 | 5.1 | 3 | entrectinib 600 mg daily | 21.9 | false | MSI-H | 2026-03-15T05:35:59.223613+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789876 | REC_0009580 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 9.7 | 66 | female | 1 | 9 | 8.7 | 8 | sotorasib 960 mg daily | 7.8 | true | MSS | 2026-03-15T05:35:59.223841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996647 | REC_0009581 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 7.2 | 50 | male | 0 | 43 | 6.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 10.4 | true | MSS | 2026-03-15T05:35:59.224182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_866430 | REC_0009582 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 10.8 | 78 | female | 2 | 13 | 5.1 | 1 | alectinib 600 mg BID | 19.6 | false | MSS | 2026-03-15T05:35:59.224480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571788 | REC_0009583 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 14 | 14.1 | 56 | female | 1 | 16 | 6.6 | 6 | osimertinib 80 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:35:59.224722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_453626 | REC_0009584 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 9.3 | 68 | female | 0 | 42 | 5.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.7 | false | MSS | 2026-03-15T05:35:59.224952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_966862 | REC_0009585 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 10.6 | 67 | female | 1 | 6 | 5.1 | 2 | entrectinib 600 mg daily | 19 | false | MSS | 2026-03-15T05:35:59.225191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985068 | REC_0009586 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 13.2 | 62 | male | 1 | 20 | 5.5 | 7 | osimertinib 80 mg daily | 9.4 | false | MSI-H | 2026-03-15T05:35:59.225426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150915 | REC_0009587 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7 | 61 | female | 0 | 41 | 4.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 10 | true | MSS | 2026-03-15T05:35:59.225658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540849 | REC_0009588 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 15 | 13.6 | 65 | female | 0 | 9 | 5.3 | 5 | osimertinib 80 mg daily | 5.6 | true | MSI-H | 2026-03-15T05:35:59.225893+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590329 | REC_0009589 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10.8 | 62 | female | 1 | 19 | 4.7 | 6 | alectinib 600 mg BID | 12.5 | false | MSI-H | 2026-03-15T05:35:59.226129+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643444 | REC_0009590 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 21.1 | 52 | male | 0 | 19 | 4 | 0 | sotorasib 960 mg daily | 47.1 | false | MSI-H | 2026-03-15T05:35:59.226366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277814 | REC_0009591 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 13.7 | 65 | male | 0 | 26 | 3.9 | 1 | sotorasib 960 mg daily | 24 | true | MSS | 2026-03-15T05:35:59.226602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397285 | REC_0009592 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.4 | 67 | female | 0 | 18 | 6 | 5 | alectinib 600 mg BID | 9.4 | true | MSI-H | 2026-03-15T05:35:59.226833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_178112 | REC_0009593 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 10.8 | 69 | female | 0 | 16 | 4.3 | 6 | osimertinib 80 mg daily | 8.9 | false | MSS | 2026-03-15T05:35:59.227069+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_199874 | REC_0009594 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 15.3 | 72 | female | 1 | 11 | 5.1 | 1 | alectinib 600 mg BID | 22.1 | true | MSI-H | 2026-03-15T05:35:59.227303+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995900 | REC_0009595 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 5.2 | 78 | female | 2 | 26 | 6.8 | 3 | pembrolizumab 200 mg q3w | 19.1 | false | MSS | 2026-03-15T05:35:59.227572+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194910 | REC_0009596 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 7.6 | 80 | female | 2 | 41 | 6.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 32.5 | true | MSS | 2026-03-15T05:35:59.227809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839600 | REC_0009597 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 17.4 | 62 | female | 0 | 4 | 6.1 | 4 | entrectinib 600 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:59.228049+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731932 | REC_0009598 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 8.7 | 55 | female | 1 | 14 | 5.4 | 1 | osimertinib 80 mg daily | 24.8 | false | MSS | 2026-03-15T05:35:59.228349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449135 | REC_0009599 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6 | 67 | female | 0 | 59 | 3.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.1 | false | MSS | 2026-03-15T05:35:59.228584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623751 | REC_0009600 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 12.5 | 71 | female | 2 | 24 | 4.3 | 2 | entrectinib 600 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:59.228820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.